drugset / Trial / NCT01548391
A Phase I Clinical Study Study of the Safety, Tolerability, and Pharmacokinetics of HX-1171 in Healthy Male Subjects
RandomizedSingle-groupSingle-blindSupportive care
Summary
This study is designed to evaluate the safety, tolerability, and pharmacokinetics of HX-1171 in healthy male subjects.
Timeline
- Start
- 2012-03
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HX-1171 | Small molecule | 20 mg | — |
| Subject | HX-1171 | Small molecule | 40 mg | — |
| Subject | HX-1171 | Small molecule | 80 mg | — |
| Subject | HX-1171 | Small molecule | 160 mg | — |
| Subject | HX-1171 | Small molecule | 300 mg | — |
| Subject | HX-1171 | Small molecule | 600 mg | — |
| Subject | HX-1171 | Small molecule | 1200 mg | — |
| Subject | HX-1171 | Small molecule | 1500 mg | — |
| Subject | HX-1171 | Small molecule | 2000 mg | — |
Indications
No indication recorded.